-
公开(公告)号:JP2013177405A
公开(公告)日:2013-09-09
申请号:JP2013091454
申请日:2013-04-24
Applicant: Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
Inventor: LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
IPC: C07K16/24 , A61K39/395 , A61P1/04 , A61P1/14 , A61P1/16 , A61P3/10 , A61P5/00 , A61P7/06 , A61P9/02 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/02 , A61P17/04 , A61P17/06 , A61P17/14 , A61P19/02 , A61P25/04 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P25/32 , A61P27/02 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P31/14 , A61P31/18 , A61P31/20 , A61P33/00 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C12N15/02 , C12N15/09 , C12P21/08
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , C07K2317/24 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/6869
Abstract: PROBLEM TO BE SOLVED: To provide an antibody that binds with IL-12p40 binding protein, particularly human interleukin 12 (hIL-12) and/or human IL-23 (hIL-23), especially a chimera antibody, a CDR graft antibody and a humanized antibody.SOLUTION: A preferred antibody has a high affinity to hIL-12 and/or hIL-23, and neutralizes hIL-12 and/or hIL-23 activity in vitro and in vivo. The present antibody may be a full length antibody or an antigen binding part thereof. The present antibody or antibody part is useful for example to detect hIL-12 and/or hIL-23, and to inhibit hIL-12 and/or hIL-23 activity in human subject having a disorder harmfully caused by hIL-12 and/or hIL-23 activity.
Abstract translation: 要解决的问题:提供与IL-12p40结合蛋白特别是人白介素12(hIL-12)和/或人IL-23(hIL-23),特别是嵌合体抗体,CDR移植抗体和 人源化抗体。解决方案:优选的抗体对hIL-12和/或hIL-23具有高亲和力,并且在体外和体内中和hIL-12和/或hIL-23活性。 本抗体可以是全长抗体或其抗原结合部分。 本抗体或抗体部分例如可用于检测hIL-12和/或hIL-23,并且抑制hIL-12和/或hIL-23活性,其具有由hIL-12和/或 hIL-23活动。
-
公开(公告)号:EP2064336A4
公开(公告)日:2010-03-17
申请号:EP07873427
申请日:2007-09-07
Applicant: ABBOTT LAB
Inventor: WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
CPC classification number: A61K45/06 , A61K38/00 , A61K39/3955 , C07K14/47 , C07K16/244 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号:WO2008127271A3
公开(公告)日:2009-04-09
申请号:PCT/US2007019660
申请日:2007-09-07
Applicant: ABBOTT LAB , WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
Inventor: WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
CPC classification number: A61K45/06 , A61K38/00 , A61K39/3955 , C07K14/47 , C07K16/244 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention encompasses IL- 13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hlL-13 activity, e.g., in a human subject suffering from a disorder in which hTL-13 activity is detrimental.
Abstract translation: 本发明包括IL-13结合蛋白。 具体地,本发明涉及作为嵌合,CDR移植和人源化抗体的抗体。 优选的抗体对hIL-13具有高亲和力,并在体外和体内中和hIL-13活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-13和抑制hIL-13活性,例如在患有hTL-13活性有害的病症的人类受试者中。
-
公开(公告)号:WO2007005608A3
公开(公告)日:2008-10-09
申请号:PCT/US2006025584
申请日:2006-06-29
Applicant: ABBOTT LAB , LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
Inventor: LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
IPC: C07K16/00
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , C07K2317/24 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/6869
Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
Abstract translation: 本发明包括IL-12p40结合蛋白,特别是结合人白细胞介素-12(hIL-12)和/或人IL-23(hIL-23)的抗体。 具体地,本发明涉及作为嵌合,CDR移植和人源化抗体的抗体。 优选的抗体对hIL-12和/或hIL-23具有高亲和力,并在体外和体内中和h IL-12和/或hIL-23活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-12和/或hIL-23和用于抑制hIL-12和/或hIL-23活性,例如在患有hIL -12和/或hIL-23活性是有害的。
-
公开(公告)号:EP1907421A4
公开(公告)日:2012-03-28
申请号:EP06785967
申请日:2006-06-29
Applicant: ABBOTT LAB
Inventor: LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
IPC: C07K16/24
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , C07K2317/24 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/6869
-
公开(公告)号:CR20130154A
公开(公告)日:2013-05-23
申请号:CR20130154
申请日:2013-04-03
Applicant: ABBOTT LAB
Inventor: LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
IPC: C07K16/00
Abstract: Proteínas de unión a IL-12 p40, en particular anticuerpos que se unen a la interleuquina-12 humana (hIL-12) y/o IL-23 humana (hIL-23). Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados. Los anticuerpos preferidos tienen gran afinidad por hIL-12 y/o hIL-23 y neutralizan la actividad de hIL-12 y/o hIL-23 in vitro y in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa o una porción de unión al antígeno del mismo. También se provee un método de elaboración y un método de uso de los anticuerpos de la invención.
-
公开(公告)号:CR20130152A
公开(公告)日:2013-05-23
申请号:CR20130152
申请日:2013-04-03
Applicant: ABBOTT LAB
Inventor: LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
IPC: C07K16/00
Abstract: Proteínas de unión a IL-12 p40, en particular anticuerpos que se unen a la interleuquina-12 humana (hIL-12) y/o IL-23 humana (hIL-23). Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados. Los anticuerpos preferidos tienen gran afinidad por hIL-12 y/o hIL-23 y neutralizan la actividad de hIL-12 y/o hIL-23 in vitro y in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa o una porción de unión al antígeno del mismo.
-
公开(公告)号:CR20130151A
公开(公告)日:2013-05-23
申请号:CR20130151
申请日:2013-04-03
Applicant: ABBOTT LAB
Inventor: LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
IPC: C07K16/00
Abstract: Proteínas de unión a IL-12 p40, en particular anticuerpos que se unen a la interleuquina-12 humana (hIL-12) y/o IL-23 humana (hIL-23). Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados.
-
公开(公告)号:RU2472807C2
公开(公告)日:2013-01-20
申请号:RU2009113026
申请日:2007-09-07
Applicant: ABBOTT LAB
Inventor: VU CHENBIN , DIKSON RICHARD V , BELK DZHONATAN P , IN KHUA , ARDZHIRIADI MARIJA A , KAFF KEHROLIN A , KHINTON POL R , KUMAR SHANKAR , MELIM TERRI L , CHEHN JAN
Abstract: Настоящееизобретениеотноситсяк областииммунологии. Предложенсвязывающийбелок, специфичныйк IL-13, содержащий 6CDR участков (триизлегкойи триизтяжелойцепи). Раскрытыконструкцияантителанаосновеэтогобелкаи конъюгатнаосновеантитела. Описаны: вариантыНК, кодирующейантителоиликонструкцию, атакжевекторэкспрессии, векторрепликациии клетки, несущиетакиевектора. Описанспособполучениябелкапутемкультивированияклеткии белок, полученныйуказаннымспособом. Описаныкомпозициинаосновевариантовбелков. Использованиеизобретенияможетнайтиприменениев медицинев лечениии диагностикезаболеваний, связанныхактивностью IL-13, негативновлияющейназдоровье. 13 н. и 37 з.п. ф-лы, 23 табл., 2 пр.
-
公开(公告)号:RU2461571C2
公开(公告)日:2012-09-20
申请号:RU2008103312
申请日:2006-06-29
Applicant: ABBOTT LAB
Inventor: LEHJSI S JUZAN EH , FANG EHMMA , BELK DZHONATAN P , DIKSON RICHARD V , ROGUSKA MAJKL , KHINTON POL R , KUMAR SHANKAR
Abstract: Настоящееизобретениеотноситсяк областииммунологии. Предложеноантитело, котороехарактеризуетсятем, чтосвязываетсубъединицур40 IL-12 человекаи содержитшесть CDR областей (CDR1, CDR2, CDR3 излегкойи CDR1, CDR2, CDR3 изтяжелойцепи). Описаны: конструкцияантитела; конъюгатантитела; вариантыкодирующейнуклеиновойкислоты; вариантывекторов (дляэкспрессиии репликации); вариантыклетки-хозяина; способполученияантитела; вариантыкомпозиций; вариантыспособалечениясубъекта, имеющегонеблагоприятнуюактивность IL-12; вариантыспособауменьшенияактивности IL-12 учеловека. Использованиеизобретенияможетнайтиприменениев медицинедляпрофилактикии леченияострыхи хроническихзаболеваний, имеющихсвязьс активностьюсубъединицыр40 человека. 18 н. и 97 з.п. ф-лы, 24 табл., 2 пр.
-
-
-
-
-
-
-
-
-